ClinicalTrials.gg
Active, not recruitingNCT07849660Updated Sep 30, 2026

Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC)

An observational study in Carcinoma, Hepatocellular, sponsored by Eisai Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Eisai Inc. · Observational

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
170
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd. — none open to participants now, 4 under way, none of them phase 3. Carcinoma, Hepatocellular · Eisai Co., Ltd..

Started
2025
the only one that year
Observational
6 of 20
none open now
Registered
20th of 20
by date

Among the 20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd., this one is the only one that started in 2025, is one of 6 observational ones, and was the 20th registered.

Carcinoma, Hepatocellular

3,653 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

None of the 20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd. is open now. The open studies under Carcinoma, Hepatocellular, anywhere →

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd. as a file.
02

Study summary

This observational study will use existing real-world data from routine clinical care to describe patients with uHCC who received lenvatinib. The study will include two groups: patients who started lenvatinib as first-line (1L) treatment and patients who started lenvatinib as second-line (2L) treatment after prior 1L immunotherapy was stopped because the cancer progressed or because of toxicity. All study information will be collected retrospectively from existing patient records. Patients will be followed from the start of lenvatinib until death or their last documented follow-up before data extraction.

The primary objectives of this study are:

  • To retrospectively evaluate the effectiveness of 1L lenvatinib in a real-world setting as measured by overall survival (OS)
  • To retrospectively evaluate the effectiveness of 2L lenvatinib as measured by OS after progression on or discontinuation of prior 1L immunotherapy

    • 1L immunotherapies to be considered include atezolizumab plus bevacizumab (Atezo/Bev) or durvalumab plus tremelimumab (Durva/Treme) combination therapies, based on preferred regimens listed by National Comprehensive Cancer Network (NCCN) 2025 guidelines
03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients in both Cohorts must be adults with uHCC not amenable to locoregional therapy (LRT), diagnosed from 01 Sept 2020 to 30 Sept 2023, and confirmed by radiology, histology, or cytology. They will be excluded for main portal vein invasion (Vp4), esophageal or gastric variceal bleeding within 6 months before the index date, concurrent malignancy requiring active treatment (except non-melanoma skin cancer or curatively treated in situ cervical cancer), or prior liver transplant.

Cohort A patients must have started 1L lenvatinib at the FDA-approved dose and have BCLC Stage B/C disease, ECOG performance status 0/1, and Child-Pugh A (score 5/6) liver function.

Cohort B patients must have received 1L atezolizumab plus bevacizumab or durvalumab plus tremelimumab, then progressed or discontinued due to toxicity, with BCLC Stage B/C disease, ECOG performance status 0/1, and Child-Pugh A (score 5/6) or B (score 7) liver function.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with uHCC, as confirmed by radiology, histology, or cytology

    • 18 years of age at the time of Lenvatinib initiation for uHCC
  • Initiated, within standard clinical practice, 1L Lenvatinib (Cohort A) or initiated 2L Lenvatinib after progression on or discontinuation (due to toxicity) of prior immunotherapy (Cohort B) between 01 Sep 2020 and 30 Sep 2023
  • BCLC Stage C disease, or BCLC Stage B disease not amenable to locoregional therapy at initial diagnosis of uHCC
  • At least one measurable target lesion at Lenvatinib initiation
  • performance status 0 or 1 at Lenvatinib initiation
  • If deceased, have a reported date of death.

Cohort A

  • A (score 5 or 6) classification of uHCC at Lenvatinib initiation
  • Initiated Lenvatinib with US FDA approved starting dose (12 mg once daily for patients weighing ≥60 kg, or 8 mg once daily for patients weighing \<60 kg

Cohort B

  • Patients may have either Child-Pugh A (score 5 or 6) or Child-Pugh B (score 7) classification of uHCC at Lenvatinib initiation

Exclusion criteria

Exclusion Criteria:

  • Vp4 at Lenvatinib initiation
  • Esophageal or gastric variceal bleeding within 6 months before the index date
  • Had a prior history of other that required active treatment; exceptions include non-melanoma skin cancer or in situ cervical cancer that has potentially curative therapy underwent
  • History of liver transplant

Cohort A

  • Received other 1L systemic therapy or LRT concurrently with Lenvatinib

Cohort B

  • Received other immunotherapy not inclusive of atezolizumab plus bevacizumab or durvalumab plus tremelimumab combination therapies
  • Received other 2L systemic therapy or LRT concurrently with Lenvatinib
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
170 participants (actual)
Patient registry
No

Groups and cohorts

  • Lenvatinib Cohort A

    Drug: Lenvatinib

  • Lenvatinib Cohort B

    Drug: Lenvatinib

Interventions

  • 12 milligram (mg) based on the participant's body weight greater than or equal to (≥) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD)

    Also known as: Lenvima

06

What researchers measure

Primary outcomes

  1. Cohort A Overall Survival (OS)

    Retrospectively evaluate the effectiveness of 1L Lenvatinib in a real-world setting

    Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)

  2. Cohort B OS

    Retrospectively evaluate the effectiveness of 2L Lenvatinib

    Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)

Secondary outcomes

  1. Best Clinical Response to Lenvatinib Therapy

    Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)

    Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)

  2. Overall Response Rate (ORR)

    Proportion of patients with a best response to Lenvatinib therapy of CR or PR

    Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)

  3. Disease Control Rate (DCR)

    Proportion of patients with a best response to Lenvatinib therapy of CR, PR, or SD

    Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)

  4. Clinical Benefit Rate (CBR)

    Proportion of patients with a best response to Lenvatinib therapy of CR, PR, or durable SD (duration of stable disease ≥23 weeks)

    Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)

  5. Progression Free Survival (PFS)

    Time from the date of Lenvatinib initiation until the date of first documented progression or death (whichever occurs first)

    Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)

  6. Progression Free Survival Post-Progression (PFS2)

    Time from the date of Lenvatinib initiation until the date of disease progression on the next-line treatment or death from any cause (whichever occurs first)

    Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)

  7. Time to Next Treatment (TTNT) from Lenvatinib Initiation

    Time from the date of Lenvatinib initiation until the date of start of next treatment

    Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)

  8. Treatment Patterns in uHCC Patients that received Lenvatinib

    Treatment patterns will include time to Lenvatinib discontinuation, duration of Lenvatinib treatment, Lenvatinib dose intensity, reasons for Lenvatinib discontinuation, percentage with and time to first Lenvatinib dose reduction, and proportion with and time to surgical resection and transplantation after Lenvatinib initiation

    Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)

  9. Relational Sequencing of All Treatment Regimens received for uHCC

    Relational sequencing will include 1L and 2L Lenvatinib, 1L immunotherapy (for Cohort B), and all subsequent treatment lines after Lenvatinib discontinuation

    Time frame: From initiation of Lenvatinib therapy until date of death or until last available follow-up before data extraction (approximately 2 years)

07

Study locations

1 site
  • Eisai Trial Site #1
    Nutley, New Jersey 07110, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartActual
Nov 17, 2025
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 15, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849660
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Nov 17, 2025
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Sep 30, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion